Financial

If it’s true that Stryker has suffered from downward pricing pressure, foreign exchange pressure and absorbed recall costs this quarter, it’s perhaps not surprising they sound a bit pessimistic. But restructuring, acquisitions and positive mix changes suggest it’s not all that bad.

St. Jude Medical, Inc. has reported sales and net earnings for the second quarter ended June 29, 2013. Background We … continue reading “Mixed Bag for St.Jude Medical Sees Cardiac Rhythm Business Propped Up by The Rest”

In its quarterly financial statement Johnson & Johnson says its sales of $17.9 billion for the second quarter of 2013, represent an increase of 8.5% as compared to the second quarter of 2012. This figure includes the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business.

Preliminary second quarter figures from surgical robotics company Intuitive Surgical, Inc. are some way off the company’s predictions. Q2 projections included sales of over $620M, which would have been a 16%+ ramp, but actual sales came in at $575M, only a 7% increase over prior year.

Israeli neuro device company, HeadSense, which is developing a non-invasive neurological monitor focused initially on an intracranial pressure application, has announced it has secured necessary financing for its venture.

Echo Therapeutics, Inc., a company developing its non-invasive Symphony® CGM System as a needle-free, wireless continuous glucose monitoring system, has issued a mid-year update to its shareholders outlining the progress it has made this year, its upcoming key strategic priorities and milestones, and its efforts to conserve cash.

Such are the wonders of the US financial disclosure rules, Edwards Lifesciences Corporation is compelled to tell us it has received a warning letter from the U.S. FDA resulting from an inspection of Edwards’ facility in Draper, Utah.

In short Orthofix International N.V. has announced its results for the first quarter ended March 31, 2013. Net sales were … continue reading “Orthofix International Q1 14% Sales Decline”

Revenue for the quarter to end March increased by 33% over prior year, reflecting the impact of several new marketing initiatives leveraging positive validation from the MASTER I trial of the Company’s MGuard™ Embolic Protection Stent (EPS™).

CareFusion Corp. has announced an agreement in principle to resolve previously disclosed government investigations related to prior sales and marketing practices for its ChloraPrep® skin preparation product and its relationships with health care professionals.

It’s interesting to see Edwards Lifesciences reporting a sales increase of over eight percent compared with a year ago (10% on constant currency basis), yet still sounding disappointed that it missed its projections. Looking forward it’s watered things down a bit too.

Integra LifeSciences has initiated a voluntary recall of certain products manufactured in its Añasco, Puerto Rico facility between December 2010 and May 2011 and between November 2012 and March 2013. It seems the Company identified that there may have been deviations from approved processes in their production rather than any specific product-related issues, but the impact on the numbers is real enough for the company to be issuing warnings of revenue and profits notices.

Biomet sees revenue increases entirely due to the DePuy trauma acquisition. Net income increased year on year after exclusion of special items.

Last week we covered the latest news from the J&J transvaginal mesh proceedings. At the time, the jury had awarded … continue reading “J&J Will Appeal New $11M Pelvic Mesh Award”

Even without the revenue following the acquisition of DePuy’s trauma business, Biomet’s SET products showed impressive double digit growth. Joints nudged up too, but it’s SET that has underpinned the company’s positive sales momentum.

Device company Biosensors International Group, Ltd., has announced financial results for its third fiscal quarter (“Q3 FY13”) and nine months ended 31 December 2012. In a newly announced arrangement the company will now co-promote its Nobori stent in Japan with Terumo, replacing the original distribution arrangement.